Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Testosterone 0.03% Ophthalmic Solution for Meibomian Gland Dysfunction
NCT00755183Phase 2Completed
- Start
- Jul 2008
- Primary completion
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of testosterone 0.03% ophthalmic solution in meibomian gland dysfunction (MGD). Started Jul 2008; status: completed.
02
Drugs
testosterone 0.03% ophthalmic solution
03
Conditions
meibomian gland dysfunction (MGD)
Beyond the preview
Go deeper on NCT00755183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00755183.